|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical epidemiology and disease burden of nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD) is defined as the presence of hepatic fat accumulation after the exclusion of other causes of hepatic steatosis, including other causes of liver disease, excessive alcohol consumption, and other conditions that may lead to hepatic steatosis. NAFLD encompasses a broad clinical spectrum ranging from nonalcoholic fatty liver to nonalcoholic steatohepatitis(NASH), advanced fibrosis, cirrhosis, and finally hepatocellular carcinoma(HCC). NAFLD is the most common liver disease in the world and NASH may soon become the most common indication for liver transplantation. Ongoing persistence of obesity with increasing rate of diabetes will increase the prevalence of NAFLD, and as this population ages, many will develop cirrhosis and end-stage liver disease. There has been a general increase in the prevalence of NAFLD, with Asia leading the rise, yet the United States is following closely behind with a rising prevalence from 15% in 2005 to 25% within 5 years. NAFLD is commonly associated with metabolic comorbidities, including obesity, type Ⅱ diabetes, dyslipidemia, and metabolic syndrome. Our understanding of the pathophysiology of NAFLD is constantly evolving. Based on NAFLD subtypes, it has the potential to progress into advanced fibrosis, end-stage liver disease and HCC. The increasing prevalence of NAFLD with advanced fibrosis, is concerning because patients appear toexperience higher liver-related and non-liver-related mortality than the general population. The increased morbidity and mortality, healthcare costs and declining health related quality of life associated with NAFLD makes it a formidable disease, and one that requires more in-depth analysis. | Brandon J Perumpail Muhammad Ali Khan Eric R Yoo George Cholankeril Donghee Kim Aijaz Ahmed | 2017 | World Journal of Gastroenterology2017，23，47： | 70 |
| 2 | Obesity and non-alcoholic fatty liver disease: Disparate associations among asian populations显示文摘obesity is a global epidemic contributing to an increas-ing prevalence of obesity-related systemic disorders, including nonalcoholic fatty liver disease. The rising prevalence of nonalcoholic steatohepatitis(NASh) will in the near future lead to end-stage liver disease in a large cohort of patients with NASh-related cirrhosis and NASh is predicted to be a leading indication for liver transplantation in the coming decade. however, the prevalence of obesity and the progression of hepatic histological damage associated with NASh exhibit sig-nificant ethnic disparities. Despite a significantly lower body mass index and lower rates of obesity compared to other ethnic groups, Asians continue to demonstrate a significant prevalence of hypertension, diabetes, met-abolic syndrome and NASh. Ethnic disparities in central adiposity and visceral fat distribution have been hy-pothesized to contribute to these ethnic disparities. The current review focuses on the epidemiology of obesity and NASh among Asian populations. | Robert J Wong Aijaz Ahmed | 2014 | World Journal of Hepatology2014，6，5： | 15 |
| 3 | Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma显示文摘An increase in the prevalence of obesity and diabetes mellitus has been associated with the rise in non-alcoholic fatty liver disease(NAFLD). Two-thirds of the obese and diabetic populations are estimated to develop NAFLD. Currently, NAFLD is the most common etiology for chronic liver disease globally. The clinical spectrum of NAFLD ranges from simple steatosis, an accumulation of fat greater than 5% of liver weight, to nonalcoholic steatohepatitis(NASH), a more aggressive form with necroinflammation and fibrosis. Among the patients who develop NASH, up to 20% may advance to cirrhosis and are at risk for complications of end-stage liver disease. One of the major complications observed in patients with NASH-related cirrhosis is hepatocellular carcinoma(HCC), which has emerged as the sixth most common cancer and second leading etiology of cancer-related deaths worldwide. The incidence of HCC in the United States alone has tripled over the last three decades. In addition, emerging data are suggesting that a small proportion of patients with NAFLD may be at higher risk for HCC in the absence of cirrhosis - implicating obesity and diabetes mellitus as potential risk factors for HCC. | Fauzia Z Khan Ryan B Perumpail Robert J Wong Aijaz Ahmed | 2015 | World Journal of Hepatology2015，7，18： | 10 |
| 4 | Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease:Potential mechanistic pathways显示文摘Although hepatocellular carcinoma(HCC) primarily arises in the background of liver cirrhosis,the development of HCC in nonalcoholic fatty liver disease(NAFLD) without cirrhosis is increasingly recognized. The pathogenesis of NAFLD associated non-cirrhotic HCC is distinct from that of cirrhotic HCC because the metabolic syndrome(MS) along with obesity and insulin resistance(IR) underlie several unique mechanisms that promote tumorigenesis. IR associated with MS,NAFLD,and type 2 diabetes mellitus lead to the release of multiple pro-inflammatory cytokines,including tumor necrosis factor alpha,interleukin-6,leptin and resistin,as well as decreased amounts of adiponectin. These processes favor the development of hepatic steatosis and inflammation within the liver,which precede HCC development. Nevertheless,further investigation is necessary to elucidate the determinants for development of HCC in patients with NAFLD in the absence of cirrhosis. | Ryan B Perumpail Andy Liu Robert J Wong Aijaz Ahmed Stephen A Harrison | 2015 | World Journal of Hepatology2015，7，22： | 6 |
| 5 | Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.显示文摘 | Robert J. Wong Ramsey Cheung Aijaz Ahmed | 2014 | Hepatology2014，，： | 6 |
| 6 | Advances in alcoholic liver disease:An update on alcoholic hepatitis显示文摘Alcoholic hepatitis is a pro-inflammatory chronic liver disease that is associated with high short-term morbidity and mortality(25%-35% in one month) in the setting of chronic alcohol use. Histopathology is notable for micro- and macrovesicular steatosis, acute inflammation with neutrophil infiltration, hepatocellular necrosis, perivenular and perisinusoidal fibrosis, and Mallory hyaline bodies found in ballooned hepatocytes. Other findings include the characteristic eosinophilic fibrillar material(Mallory's hyaline bodies) found in ballooned hepatocytes. The presence of focal intense lobular infiltration of neutrophils is what typically distinguishes alcoholic hepatitis from other forms of hepatitis, in which the inflammatory infiltrate is primarily composed of mononuclear cells. Management consists of a multidisciplinary approach including alcohol cessation, fluid and electrolyte correction, treatment of alcohol withdrawal, and pharmacological therapy based on the severity of the disease. Pharmacological treatment for severe alcoholic hepatitis, as defined by Maddrey's discriminant factor ≥ 32, consists of either prednisolone or pentoxifylline for a period of four weeks. The body of evidence for corticosteroids has been greater than pentoxifylline, although there are higher risks of complications. Recently head-to-head trials between corticosteroids and pentoxifylline have been performed, which again suggests that corticosteroids should strongly be considered over pentoxifylline. | Randy Liang Andy Liu Ryan B Perumpail Robert J Wong Aijaz Ahmed | 2015 | World Journal of Gastroenterology2015，21，42： | 5 |
| 7 | New hope for hepatitis C virus:Summary of global epidemiologic changes and novel innovations over 20 years显示文摘Hepatitis C virus(HCV)is a global health concern associated with significant morbidity and mortality.Before the approval of second-generation direct-acting antiviral agents(DAAs),interferon therapy and liver transplantation constituted the mainstay of treatment.The introduction of well-tolerated oral DAAs in late 2013 has revolutionized HCV management with over 95%cure rates.The predominance of HCV-related liver transplantations has declined following the widespread approval of DAAs.Despite the unparallel efficacy observed among these novel therapies,pharmaceutical costs continue to limit equitable access to healthcare and likely contribute to the differential HCV infection rates observed globally.To reduce the burden of disease worldwide,essential agenda items for all countries must include the prioritization of integrated care models and access to DAAs therapies.Through transparent negotiations with the pharmaceutical industry,the consideration for compassionate release of medications to promote equitable division of care is paramount.Here we provide a literature review of HCV,changes in epidemiologic trends,access issues for current therapies,and global inequities in disease burden. | Brittany B Dennis Leen Naji Yasmin Jajarmi Aijaz Ahmed Donghee Kim | 2021 | World Journal of Gastroenterology2021，27，29： | 4 |
| 8 | Nonalcoholic Steatohepatitis is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the U.S.显示文摘 | Robert J. Wong Maria Aguilar Ramsey Cheung Ryan B. Perumpail Stephen A. Harrison Zobair M. Younossi Aijaz Ahmed | 2014 | Gastroenterology2014，，： | 3 |
| 9 | Advances in cirrhosis: Optimizing the management of hepatic encephalopathy显示文摘Hepatic encephalopathy(HE) is a major complication of cirrhosis resulting in significant socioeconomic burden, morbidity, and mortality. HE can be further subdivided into covert HE(CHE) and overt HE(OHE). CHE is a subclinical, less severe manifestation of HE and requires psychometric testing for diagnosis. Due to the time consuming screening process and lack of standardized diagnostic criteria, CHE is frequently underdiagnosed despite its recognized role as a precursor to OHE. Screening for CHE with the availability of the Stroop test has provided a pragmatic method to promptly diagnose CHE. Management of acute OHE involves institution of lactulose, the preferred first-line therapy. In addition, prompt recognition and treatment of precipitating factors is critical as it may result in complete resolution of acute episodes of OHE. Treatment goals include improvement of daily functioning, evaluation for liver transplantation, and prevention of OHE recurrence. For secondary prophylaxis, intolerance to indefinite lactulose therapy may lead to non-adherence and has been identified as a precipitating factor for recurrent OHE. Rifaximin is an effective add-on therapy to lactulose for treatment and prevention of recurrent OHE. Recent studies have demonstrated comparable efficacy of probiotic therapy to lactulose use in both primary prophylaxis and secondary prophylaxis. | Andy Liu Ryan B Perumpail Radhika Kumari Zobair M Younossi Robert J Wong Aijaz Ahmed | 2015 | World Journal of Hepatology2015，7，29： | 3 |
| 10 | 利用双向回交导入系定位水稻苗期耐亚铁毒和锌毒的QTL显示文摘铁和锌是水稻生长必需的微量元素,但在低洼或酸性土壤中,过量的二价铁和锌对水稻生长具毒害作用,最终造成生物量和产量下降。为探讨水稻苗期耐亚铁毒、锌毒的遗传机制,利用优质粳稻品种Lemont和高产籼稻品种特青为亲本构建的高代双向回交导入系和308个在染色体上均匀分布的SNP标记剖析耐亚铁毒、锌毒相关的QTL。从双向导入系共检测到42个影响耐亚铁毒、锌毒相关性状如苗高、苗干重、根干重以及胁迫与对照相对值的QTL,多数位点增强亚铁毒、锌毒抗性的有利等位基因来自Lemont。其中同时在2个背景下表达的QTL有4个,占定位QTL总数的9.52%,说明大多数QTL的表达具有明显的遗传背景效应。同一遗传背景下同时影响耐亚铁毒和锌毒的QTL有9个,其中QSdw5在2个背景中均被检测到,其效应大小和方向一致,说明水稻苗期耐亚铁毒、锌毒之间存在遗传重叠位点。因此,通过分子标记辅助选择从Lemont中导入或聚合有利的遗传重叠区域,可以提高特青对亚铁毒、锌毒的抗性水平。 | 张建 Aijaz Ahmed SOOMRO 柴路 崔彦茹 王小倩 郑天清 徐建龙 黎志康 | 2013 | 作物学报2013，39，10： | 2 |
| 11 | Hepatitis E virus infection in the liver transplant recipients:Clinical presentation and management显示文摘Hepatitis E virus(HEV) is an emerging pathogen and an increasingly recognized cause of graft hepatitis, especially in the post-orthotopic liver transplantation immunocompromised population. The exact incidence and prevalence of HEV infection in this population remains unclear but is certainly greater than historical estimates. Identifying acute HEV infection in this population is imperative for choosing the right course of management as it is very difficult to distinguish histologically from acute rejection on liver biopsy. Current suggested approach to manage acute HEV involves modifying immunosuppression, especially discontinuing calcineurin inhibitors which are the preferred immunosuppressive agents post-orthotopic liver transplantation. The addition of ribavirin monotherapy has shown promising success rates in clearing HEV infection and is used commonly in reported cases. | Avin Aggarwal Ryan B Perumpail Swetha Tummala Aijaz Ahmed | 2016 | World Journal of Hepatology2016，8，2： | 2 |
| 12 | Serum levels of TNF-α in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus显示文摘 | Gauhar Hussain S. Aijaz Abbas Rizvi Sangeeta Singhal Jamal Ahmad | 2013 | Diabetes & Metabolic Syndrome: Clinical Research & Reviews2013，，： | 2 |
| 13 | Dermatologic Disorders Associated With Chronic Hepatitis C: Effect of Interferon Therapy显示文摘 | David R. Berk Susan Bayliss Mallory Emmet B. Keeffe Aijaz Ahmed | 2007 | Clinical Gastroenterology and Hepatology2007，，2： | 1 |
| 14 | Evidence of Grapevine leafroll associated virus-1–3, Grapevine fleck virus and Grapevine virus B Occurring in Himachal Pradesh, India显示文摘 | Surender Kumar Lakhmir Singh Luca Ferretti Marina Barba Aijaz A. Zaidi Vipin Hallan | 2013 | Indian Journal of Virology2013，，1： | 1 |
| 15 | NeurocognitiVe function in children with compen-sated hypothyroidism:lack of short term effects on or off thyroxin显示文摘 | AIJAZ N J FLAHERTY E M PRESTON T | 2006 | BMC Endocr Disord2006，6，： | 1 |
| 16 | Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma显示文摘BACKGROUND Recurrent hepatitis C virus(HCV)infection of transplanted liver allografts is universal in patients with detectable HCV viremia at the time of transplantation.Direct-acting antiviral(DAA)therapy has been adopted as the standard of care for recurrent HCV infection in the post-transplant setting.However,there are insufficient data regarding its efficacy in liver transplant(LT)recipients with a history of hepatocellular carcinoma(HCC),and the risk of HCC recurrence after DAA therapy is unknown.predictors of DAA treatment failure and HCC recurrence in LT recipients.METHODS A total of 106 LT recipients given DAAs for recurrent HCV infection from 2015 to 2019 were identified(68 with and 38 without HCC).Descriptive statistics and logistic regression models were used to estimate the multivariate odds ratios and respective 95%confidence intervals for predictors of treatment failure and HCC recurrence.RESULTS Six patients(6%)experienced DAA therapy failure post-LT and 100(94%)had a sustained virologic response at follow-up week 12.A high alanine transaminase level>35 U/L at treatment week 4 was a significant predictor of treatment failure.Relapse to pre-LT DAA therapy is a predictor of post-LT HCC recurrence,P=0.04.DAA relapse post-LT was also associated with post-transplantation HCC recurrence,P=0.05.CONCLUSION DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC.Relapse to pre-and post-LT DAA therapy is associated with post-transplantation HCC recurrence. | Mohamed Saleh Ismail Manal Hassan Saira Aijaz Khaderi Wael Ahmed Yousry Maha Mohsen Kamal El-Din Mohamed Mohamed Bahaa El-Din Osama Aboelfotoh El Sayed Ahmed Omar Kaseb John Alan Goss FasihaKanwal Prasun Kumar Jalal | 2020 | World Journal of Hepatology2020，12，9： | 1 |
| 17 | Current indications and contraindications for liver transplantation显示文摘 | Aijaz Ahmed | 2007 | Clin Liver Dis2007，11，1： | 1 |
| 18 | CRB-MAC: A receiver-based MAC protocol for cognitive radio equipped smart grid sensor networks 显示文摘 | Aijaz A Ping S Y Akhavan M R | 2014 | IEEE Sensors Journal2014，14，12： | 1 |
| 19 | Use of direct-acting antiviral agents in hepatitis C virusinfected liver transplant candidates显示文摘Since the advent of direct acting antiviral(DAA) agents, chronic hepatitis C virus(HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant(LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response(SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-transplant period. | Chiranjeevi Gadiparthi George Cholankeril Brandon J Perumpail Eric R Yoo Sanjaya K Satapathy Satheesh Nair Aijaz Ahmed | 2018 | World Journal of Gastroenterology2018，24，3： | 1 |
| 20 | Mutations in HBV DNA Polymerase Associated with Nucleos(t)ide resistance are Rare in Treatment-na?ve Patients显示文摘 | Philip Vutien Huy N. Trinh Ruel T. Garcia Huy A. Nguyen Brian S. Levitt Khanh Nguyen Eduardo da Silveira Tami Daugherty Aijaz Ahmed Gabriel Garcia Glen A. Lutchman Mindie H. Nguyen | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员